Condition
McCune-Albright Syndrome
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Completed3
Withdrawn1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00001727RecruitingPrimary
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
NCT00278915Phase 2Completed
Faslodex in McCune-Albright Syndrome
NCT03520153WithdrawnPrimary
Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome
NCT00318097CompletedPrimary
Histamine Responsiveness in McCune-Albright Syndrome
NCT00055302Phase 2CompletedPrimary
Arimidex in McCune Albright Syndrome
Showing all 5 trials